Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:1.9.3.1 (
cytochrome oxidase
)
8,822
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
DAZAP1
is an evolutionarily conserved RNA-binding protein expressed in many tissues in mice and humans.
DAZAP1
-knockout mice carrying a partial loss-of-function (hypomorphic) allele exhibited severe deficiencies in spermatogenesis and cell growth, indicating that
DAZAP1
plays a pivotal role in the development of germ and somatic cells. We have identified cox6c mRNA, which encodes a subunit of
complex IV
of the mitochondrial respiratory chain, as a target transcript regulated by
DAZAP1
. We found that
DAZAP1
bound to cox6c mRNA derived from either the genomic DNA or a genome-type expression vector in cells, but not to cox6c mRNA derived from an intronless expression vector. Interestingly, the presence of the last intron was sufficient for
DAZAP1
binding to the mRNA, suggesting specific intron dependent
DAZAP1
loading onto cox6c mRNA. Overexpression of
DAZAP1
resulted in the accumulation of cox6c pre-mRNA for all introns, implying that
DAZAP1
reduces pre-mRNA splicing efficiency. In addition, the reduction of mature cox6c mRNA levels led to decreases in the COX6C protein levels. Both
DAZAP1
knockdown and COX6C overexpression retarded cell growth. The lines of evidence presented here reveal that
DAZAP1
is a negative regulator of pre-mRNA splicing and may control energy production in mitochondria by regulating COX6C expression. The
DAZAP1
functions described in this study may also account for the phenotypes observed in the
DAZAP1
hypomorphic mice.
...
PMID:Specific intron-dependent loading of DAZAP1 onto the cox6c transcript suppresses pre-mRNA splicing efficacy and induces cell growth retardation. 2950 34